Form 4: Disc Medicine Director Sells $1.9M in Shares

Disc Medicine Director Kevin Bitterman sold over 32,000 shares of common stock for approximately $1.9 million through pre-planned transactions.

Summary

• Director Kevin Bitterman, also a 10% owner of Disc Medicine, Inc. (IRON), sold a total of 32,174 shares of common stock.
• The sales occurred in two separate transactions on August 13, 2025, and August 14, 2025.
• On August 13, 2025, 24,962 shares were sold at a weighted average price of $61.15 per share, with prices ranging from $60.95 to $61.615.
• On August 14, 2025, an additional 7,212 shares were sold at a weighted average price of $60.99 per share, with prices ranging from $60.95 to $61.11.
• The total estimated proceeds from these sales amount to approximately $1,966,860.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan established on January 31, 2025.
• Following these sales, Kevin Bitterman retains significant indirect beneficial ownership through various Atlas Venture funds, including 592,908 shares via Atlas Venture Opportunity Fund I, LP, 420,549 shares via Atlas Venture Opportunity Fund II, LP, and 51,000 shares via Atlas Venture Fund XII, L.P., while disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. While insider selling can be perceived negatively, the use of a Rule 10b5-1 plan indicates a pre-planned, non-event-driven transaction, mitigating immediate negative sentiment. The director still retains significant indirect beneficial ownership.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new negative company developments or insider information.

Negatives

• A director and 10% owner selling a significant number of shares could be perceived negatively by the market, potentially signaling a lack of confidence, even if pre-planned.

Future Outlook

NA

Industry Context

Insider selling, even when pre-planned, is a common occurrence in the biotechnology and pharmaceutical industries, particularly for venture capital partners who may need to realize gains or manage fund distributions. This type of transaction does not inherently signal a negative outlook for the company's pipeline or market position unless accompanied by other adverse news.

Comparison to Industry Standards

• Insider sales via Rule 10b5-1 plans are standard practice for executives and directors to manage personal finances and diversify holdings while avoiding accusations of trading on material non-public information.
• The sale amount, while significant in absolute terms, represents a small fraction of the total indirect holdings of the Atlas Venture funds, which still collectively hold over 1 million shares.
• Comparable situations often involve venture capital partners divesting portions of their holdings in successful portfolio companies as they mature or reach certain valuation milestones, similar to divestments seen from directors associated with funds like Flagship Pioneering or OrbiMed in other biotech firms.

Related Party Transactions

• The sales were conducted by Kevin Bitterman, a director and 10% owner, through entities (Atlas Venture funds) in which he has a pecuniary interest, making these related-party transactions in terms of beneficial ownership changes.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to short-term price volatility, though the 10b5-1 plan mitigates this perception.
• Employees and management are unlikely to experience direct impact, as this is a pre-planned financial transaction by a director.

Key Dates

Recommendation

The insider selling, while significant in dollar value, was conducted under a pre-arranged Rule 10b5-1 plan, which suggests it's a planned financial event rather than a reaction to new negative company information. The director retains substantial indirect beneficial ownership through the Atlas Venture funds. Given the pre-planned nature and continued significant holdings, a 'hold' recommendation is appropriate as this event alone does not fundamentally alter the investment thesis for Disc Medicine, Inc.

Keywords

Disc Medicine, IRON, Insider Selling, Form 4, SEC Filing, Director Stock Sale, Rule 10b5-1, Biotechnology, Pharmaceuticals, Atlas Venture